Enlight-LN Registry: Baseline Demographics and Clinical Characteristics of an Initial Cohort of Patients Treated with Voclosporin for Lupus Nephritis in the United States (NKF-SCM 2024) - Mar 23, 2024 - Abstract #369; P | "The Phase 3 AURORA 1 study demonstrated that adding voclosporin to mycophenolate mofetil and low-dose glucocorticoids led to earlier reductions in proteinuria, with long-term safety over three years in patients continuing treatment in the AURORA 2 continuation study. Baseline data on this initial cohort of patients are reflective of the larger LN population in the US. Enrollment of additional patients and ongoing data collection will provide valuable insight into the real-world utilization of voclosporin."
Clinical • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
|
|
Stephen Myers; Michelle Zubrycki; Lily Cipolla; Ron Flauto
|